Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERITAC-2: ARV-471 versus fulvestrant in ER-positive, HER2-negative advanced breast cancer
jRCT2031220651Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Mar 2023
- Modality
- Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing ARV-471 with Fulvestrant (2 arms). Primary endpoint: Progression-free survival. Started Mar 2023; status: active, not recruiting.
02
Drugs
vepdegestrantfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031220651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220651.